Clinical trial
To Investigate Whether the Postprandial Blood Sugar Level as Achieved Using Ultrarapid-Acting Type Insulin Could Prevent Great Vessel Disorder in Japanese Type 2 Diabetic Patients.
NCT00575172 is registered in ClinicalTrials.gov with Osaka Saiseikai Nakatsu Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- To Investigate Whether the Postprandial Blood Sugar Level as Achieved Using Ultrarapid-Acting Type Insulin Could Prevent Great Vessel Disorder in Japanese Type 2 Diabetic Patients.
- Lead sponsor
- Osaka Saiseikai Nakatsu Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2003
- Completion date
- December 31, 2007
- Enrollment
- 346 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.